Development of therapies against neuromuscular diseases causing muscle atrophy

研究成果: Short survey

1 引用 (Scopus)

抄録

Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

元の言語English
ページ(範囲)229-233
ページ数5
ジャーナルJapanese Journal of Neuropsychopharmacology
26
発行部数5-6
出版物ステータスPublished - 01-11-2006

Fingerprint

Neuromuscular Diseases
Muscular Atrophy
Muscular Dystrophies
Muscles
Skeletal Muscle
Stem Cells
Cell- and Tissue-Based Therapy
Neurodegenerative Diseases
Genetic Therapy
Side-Population Cells
Myostatin
Therapeutics
Drug Therapy
Amyotrophic Lateral Sclerosis
Motor Neurons
Bone Marrow Cells
Muscle Cells
Adipose Tissue
Pharmacology
Inflammation

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

これを引用

@article{4c9384c5ab1a4851ac1cd9e4c0c15756,
title = "Development of therapies against neuromuscular diseases causing muscle atrophy",
abstract = "Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.",
author = "Kunihiro Tsuchida",
year = "2006",
month = "11",
day = "1",
language = "English",
volume = "26",
pages = "229--233",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "5-6",

}

TY - JOUR

T1 - Development of therapies against neuromuscular diseases causing muscle atrophy

AU - Tsuchida, Kunihiro

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

AB - Skeletal muscles become atrophied by muscular disorders such as muscular dystrophy, wasting and even aging. In addition to muscle atrophy, progressive muscle damage, inflammation and replacement of muscle fibers with fibrous and fatty tissues are observed in muscular dystrophy. Neuronal innervation is required for skeletal muscle, and muscles become atrophic when motor neurons are affected by neurodegenerative disorders such as amyotrophic lateral sclerosis. Restoring muscle mass and function lost by diseases such as muscular dystrophy and neurodegenerative disorders is important. There are three rational therapies for muscular dystrophy and related diseases: gene therapy, cell therapy and drug therapy. Gene therapies to replace the defective genes have been tried with various degrees of effectiveness. Multiple myogenic stem cells including satellite cells, bone marrow cells, muscle side population cells, muscle-derived stem cells and mesoangioblast have been characterized. Cell therapies using these stem cells are one of the promising therapies for neuromuscular diseases causing muscle atrophy. As pharmacological drug therapies, increasing skeletal muscle mass by myostatin inhibition is quite promising and will be applied clinically in the near future.

UR - http://www.scopus.com/inward/record.url?scp=33846117573&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846117573&partnerID=8YFLogxK

M3 - Short survey

C2 - 17240849

AN - SCOPUS:33846117573

VL - 26

SP - 229

EP - 233

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 5-6

ER -